id: extended_release_naltrexone_access_to_opioid_treatment_retention
name: Extended-Release Naltrexone (XR-NTX) Access â†’ Opioid Use Disorder Treatment
  Retention
from_node:
  node_id: extended_release_naltrexone_access
  node_name: Extended-Release Naltrexone (XR-NTX) Access
to_node:
  node_id: opioid_treatment_retention
  node_name: Opioid Use Disorder Treatment Retention
direction: positive
category: healthcare_access
mechanism_pathway:
- 'Step 1: XR-NTX requires monthly clinic visits for injection administration, creating
  regular treatment engagement points'
- 'Step 2: Sustained opioid receptor blockade reduces withdrawal and craving between
  visits'
- 'Step 3: Reduced symptoms and regular appointment structure support continued treatment
  participation'
- 'Step 4: Regular provider contact enables ongoing clinical monitoring and psychosocial
  support integration'
evidence:
  quality_rating: C
  n_studies: 1
  primary_citation: Paul Crits-Christoph et al. 2016. "A Naturalistic Evaluation of
    Extended-Release Naltrexone in Clinical Practice in Missouri.." *Journal of substance
    abuse treatment*. https://doi.org/10.1016/j.jsat.2016.07.014
last_updated: '2025-12-02'
version: '1.0'
llm_metadata:
  extracted_by: claude-sonnet-4-5-20250929
  extraction_date: '2025-12-02T18:12:06.693101'
  batch_id: msgbatch_01AKnPJgzm7Fk9qubgAz9GaD
moderators:
- name: comparison_medication
  direction: weakens
  strength: moderate
  description: Buprenorphine/naloxone showed superior retention compared to XR-NTX,
    suggesting different medication mechanisms affect retention differently
_source_file: /Users/mauriceelhelou/Library/CloudStorage/OneDrive-HarvardUniversity/New
  folder (2)/healthsystems/mechanism-bank/mechanisms/healthcare_access/extended_release_naltrexone_access_to_opioid_treatment_retention.yaml
_category: healthcare_access
